Evidence map›Paper›PMID 41268779›Full record

ArticleInternational journal of immunopathology and pharmacology

Translation element EIF4A1 is a potential divergent immune biomarker between colon cancer and rectal cancer.

Zhenpeng Zhu, Peng Wang, Chenyang Hou, Jiajia Xiao, Fengxu Yan, Shan Liu, Xiran Wang, Xuejun Zhi, Jun Xue, Dandan Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhenpeng ZhuHebei North University, Zhangjiakou City, Hebei Province, China.
Peng WangGraduate School of Hebei Medical University, Shijiazhuang City, Hebei Province, China.ORCID 0009-0002-1009-6416
Chenyang HouHebei North University, Zhangjiakou City, Hebei Province, China.ORCID 0009-0008-4004-5613
Jiajia XiaoHebei North University, Zhangjiakou City, Hebei Province, China.ORCID 0009-0002-2521-5713
Fengxu YanHebei North University, Zhangjiakou City, Hebei Province, China.
Shan LiuInstitute of Bio-Architecture and Bio-Interactions (IBABI), Shenzhen Medical Academy of Research and Translation (SMART), Shenzhen, China.
Xiran WangDepartment of Bioinformatics, School of Health Care, Changchun Vocational College of Health, Changchun City, Jilin Province, China.
Xuejun ZhiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, China.ORCID 0009-0009-1907-0352
Jun XueHebei Key Laboratory of Systems Biology and Gene Regulation, Department of Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou City, Hebei Province, China.
Dandan XuHebei Key Laboratory of Systems Biology and Gene Regulation, Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, China.
Fei GuoHebei Key Laboratory of Systems Biology and Gene Regulation, Department of Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou City, Hebei Province, China.
Weizheng LiangHebei Key Laboratory of Systems Biology and Gene Regulation, Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGiven the global high incidence of colorectal cancer (CRC) and the need for subtype-specific molecular targets, this study aims to investigate the role and therapeutic potential of EIF4A1 in colon and rectal cancers.

introductionThe potential of Eukaryotic translation initiation factor 4A1(EIF4A1) to guide prognosis and inform immunotherapeutic strategies in colon and rectal cancers warrants further investigation.

methodsEIF4A1 expression levels were measured by quantitative real-time PCR (qRT-PCR), and EIF4A1 protein expression was evaluated via immunohistochemistry (IHC). Additionally, multi-dimensional database analyses were performed to characterize the biological functions of EIF4A1 and explore its heterogeneity in CRC.

resultsEIF4A1 expression was upregulated in both colon and rectal cancers, with significant associations with poor survival outcomes. Functional enrichment analyses indicated that EIF4A1 was predominantly associated with the neutrophil extracellular trap (NET) network in colon cancer. Strong positive correlations between EIF4A1 expression and neutrophil infiltration were observed in both cancer subtypes. Notably, EIF4A1 exhibited divergent immune infiltration patterns: a strong positive correlation with CD8

conclusionThe heterogeneity of EIF4A1 and its differential roles in driving cancer progression between colon and rectal cancers highlight the need for subtype-specific immunotherapeutic strategies for these malignancies.

Indexed as

Colonic NeoplasmsEukaryotic Initiation Factor-4ARectal NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorComputational BiologyDisease ProgressionExtracellular TrapsFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryImmunotherapyMaleBiomarkers, TumorEIF4A1 protein, humanEukaryotic Initiation Factor-4ACRCdifferences in tumorsEIF4A1translational controltumor immunity

Identifiers

PMID41268779
PMCPMC12639241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.